Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Comment on Delanaye et al: Future perspectives regarding kidney function estimates and dose adjustments

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Opioid use is associated with increased out-of-hospital cardiac arrest risk among 40,000-cases across two countries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37,000 cases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIM: This study investigated the influence of CES1 variations, including the SNP rs71647871 (G143E) and variation in copy number, on the pharmacokinetics of a single oral dose of 10 mg methylphenidate.

METHODS: CES1 genotype was obtained from 200 healthy Danish Caucasian volunteers. Based on the genotype, 44 (19 males and 25 females) were invited to participate in an open, prospective trial involving six predefined genotypes: three groups with two, three, and four CES1 copies, respectively; a group of carriers of the CES1 143E allele; a group of individuals homozygous for CES1A1c (CES1VAR); and a group having three CES1 copies, in which the duplication, CES1A2, had increased transcriptional activity. Plasma concentrations of methylphenidate and its primary metabolites were determined at scheduled time points.

RESULTS: Median AUC of d-methylphenidate was significantly larger in the group carrying the 143E allele (53.3 ng/ml x h, range 38.6-93.9) than in the control group (21.4 ng/ml x h, range 15.7-34.9) (p < 0.0001). Median AUC of d-methylphenidate was significantly larger in the group with four CES1 copies (34.5 ng/ml x h, range 21.3-62.8) than in the control group (p = 0.01) and the group with three CES1 copies (23.8 ng/ml x h, range 15.3-32.0, p = 0.03). There was no difference between the groups with two and three copies of CES1.

CONCLUSIONS: The 143E allele resulted in an increased AUC, suggesting a significantly decreased CES1 enzyme activity. Surprisingly, this was also the case in subjects with homozygous duplication of CES1, perhaps reflecting an undiscovered mutation affecting the activity of the enzyme.

OriginalsprogEngelsk
TidsskriftBritish Journal of Clinical Pharmacology
Vol/bind83
Udgave nummer7
Sider (fra-til)1506-1514
ISSN0306-5251
DOI
StatusUdgivet - jul. 2017

ID: 49703095